Update on the Pharmacological Treatment of Alzheimer’s Disease
暂无分享,去创建一个
[1] Kenneth S. Kosik,et al. The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology , 1996, Nature Medicine.
[2] Simon Lovestone,et al. Alzheimer's disease – do tauists and baptists finally shake hands? , 2002, Trends in Neurosciences.
[3] W. Markesbery,et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. , 1997, JAMA.
[4] C. Bulpitt,et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial , 2008, The Lancet Neurology.
[5] D. Selkoe. Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.
[6] P. S. St George-Hyslop,et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. , 2002, Nature medicine.
[7] A. Fleisher,et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. , 2008, Archives of neurology.
[8] Mary Sano,et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study , 2008, The Lancet.
[9] D. Knopman,et al. The Clinician Interview‐ Based Impression (CIBI) , 1994, Neurology.
[10] A D Roses,et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[11] K. Henke,et al. Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease , 2003, Neuron.
[12] J. Raftery,et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial , 2004, The Lancet.
[13] R J Harvey,et al. Donepezil for dementia due to Alzheimer's disease. , 2006, The Cochrane database of systematic reviews.
[14] D. Westaway,et al. Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model , 2006, Nature Medicine.
[15] R O Weller,et al. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. , 2008, Brain : a journal of neurology.
[16] Johannes Kornhuber,et al. Therapeutic approaches to Alzheimer's disease. , 2006, Brain : a journal of neurology.
[17] M. Obrenovich,et al. Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Alzheimer disease , 2009, Neurotoxicity Research.
[18] C. Bocti,et al. Management of dementia with a cerebrovascular component , 2007, Alzheimer's & Dementia.
[19] G. Wilcock,et al. The cholinergic hypothesis of Alzheimer’s disease: a review of progress , 1999, Journal of neurology, neurosurgery, and psychiatry.
[20] D. Selkoe. Alzheimer Disease: Mechanistic Understanding Predicts Novel Therapies , 2004, Annals of Internal Medicine.
[21] M. Mattson,et al. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[22] B. Winblad,et al. IDEAL , 2007, Neurology.
[23] S. Lovestone,et al. Neurofibrillary tangles and tau phosphorylation. , 2001, Biochemical Society symposium.
[24] D. Butterfield,et al. Direct evidence of oxidative injury produced by the Alzheimer's β-Amyloid peptide (1–40) in cultured hippocampal neurons , 1995, Experimental Neurology.
[25] D. Bennett,et al. LONG-TERM FETAL CELL TRANSPLANT IN HUNTINGTON DISEASE: STAYIN’ ALIVE , 2007, Neurology.
[26] L. Lue,et al. Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease , 1999 .
[27] Pierre N Tariot,et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.
[28] J. Orgogozo,et al. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease , 2007, Neurology.
[29] M. Billingsley,et al. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. , 1997, The Biochemical journal.
[30] Canadian study of health and aging: study methods and prevalence of dementia. , 1994, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[31] S. Hendrix,et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial , 2008, The Lancet Neurology.
[32] T. Wisniewski,et al. Biology of Aβ Amyloid in Alzheimer's Disease , 1997, Neurobiology of Disease.
[33] F. Boller,et al. Severe impairment battery. A neuropsychological test for severely demented patients. , 1994, Archives of neurology.
[34] K. Henke,et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. , 2003, Neuron.
[35] Neil B. Minkoff,et al. Recommendations for best practices in the treatment of Alzheimer's disease in managed care. , 2006, The American journal of geriatric pharmacotherapy.
[36] A. Mackinnon,et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. , 2003, Archives of neurology.
[37] R. Collins,et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions , 2004, The Lancet.
[38] Serge Gauthier,et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial , 2002, The Lancet.
[39] B. Dubois,et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.
[40] E. Aguglia,et al. Rivastigmine in the treatment of Alzheimer’s disease: an update , 2007, Clinical interventions in aging.
[41] C. Mathers,et al. Global prevalence of dementia: a Delphi consensus study , 2005, The Lancet.
[42] L. Thal,et al. CME Practice parameter : Management of dementia ( an evidence-based review ) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .
[43] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[44] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[45] V. Lee. Disruption of the cytoskeleton in Alzheimer's disease , 1995, Current Opinion in Neurobiology.
[46] D. Westaway,et al. Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4–10 and inhibit cytotoxicity and fibrillogenesis , 2002, Nature Medicine.
[47] J. Becker,et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.
[48] Nick C Fox,et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.
[49] B. Everitt,et al. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease , 2009, International journal of geriatric psychiatry.
[50] D. Geldmacher,et al. Donepezil Is Associated with Delayed Nursing Home Placement in Patients with Alzheimer's Disease , 2003, Journal of the American Geriatrics Society.
[51] B. Seltzer,et al. Donepezil: an update , 2007, Expert opinion on pharmacotherapy.
[52] James A. Mortimer,et al. Brain Infarction and the Clinical Expression of Alzheimer Disease-Reply , 1997 .
[53] D. Royall,et al. Alzheimer disease as a vascular disorder: nosological evidence. , 2002, Stroke.
[54] J. Tuomilehto,et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial , 1998, The Lancet.
[55] J. Schneider,et al. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. , 2004, Archives of neurology.
[56] V. Lingala,et al. TREATMENT PERSISTENCY WITH RIVASTIGMINE AND DONEPEZIL IN A LARGE STATE MEDICAID PROGRAM , 2005, Journal of the American Geriatrics Society.
[57] Robert A. Dean,et al. Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease , 2006, Neurology.
[58] M. Dorais,et al. Drug Utilization Review of Cholinesterase Inhibitors in Quebec , 2008, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[59] P. Tariot,et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. , 2006, Neurology.
[60] H. Chertkow. Diagnosis and treatment of dementia: Introduction. Introducing a series based on the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia , 2007, Canadian Medical Association Journal.
[61] Stefan J. Teipel,et al. Decreased Activation Along the Dorsal Visual Pathway After a 3-Month Treatment With Galantamine in Mild Alzheimer Disease: A Functional Magnetic Resonance Imaging Study , 2009, Journal of clinical psychopharmacology.
[62] A. Wall,et al. PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD , 2008, Neurobiology of Aging.
[63] K. Rockwood,et al. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[64] J. O'Brien,et al. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology , 2006, Journal of psychopharmacology.
[65] P. Raina,et al. Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline , 2008, Annals of Internal Medicine.
[66] R. Hansen,et al. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis , 2008, Clinical interventions in aging.
[67] S. Wisniewski,et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease , 2002, Journal of neurology, neurosurgery, and psychiatry.
[68] C. Masters,et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.
[69] Neil Chapman,et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. , 2003, Archives of internal medicine.
[70] Khadija Iqbal,et al. Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles. , 1998, Journal of neural transmission. Supplementum.
[71] S. M. Sumi,et al. Amyloid β protein (Aβ) deposition in chromosome 14–linked Alzheimer's disease: Predominance of Aβ42(43) , 1996 .
[72] J. C. Torre,et al. Pathophysiology of Neuronal Energy Crisis in Alzheimer’s Disease , 2008, Neurodegenerative Diseases.
[73] N. Herrmann,et al. Persistence with Cholinesterase Inhibitor Therapy for Dementia , 2009, Drugs & aging.
[74] T. Wisniewski,et al. Biology of A beta amyloid in Alzheimer's disease. , 1997, Neurobiology of disease.
[75] J. C. Torre,et al. Alzheimer Disease as a Vascular Disorder: Nosological Evidence , 2002 .
[76] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[77] Li-sheng Liu,et al. Treatment of hypertension in patients 80 years of age or older. , 2008, The New England journal of medicine.
[78] S. Gauthier,et al. Alzheimer disease , 1981, Neurology.
[79] C. Geula,et al. Neurobiology of butyrylcholinesterase , 2003, Nature Reviews Neuroscience.
[80] N. Bohnen,et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer’s disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[81] L. Mucke,et al. Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.
[82] J. Trojanowski,et al. Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[83] B. Oken. Practice parameter: Management of dementia (an evidence-based review) , 2001, Neurology.
[84] S. M. Sumi,et al. Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta42(43). , 1996, Annals of neurology.
[85] R DeJong,et al. Measurement of quality-of-life changes in patients with Alzheimer's disease. , 1989, Clinical therapeutics.
[86] Olga Pletnikova,et al. Effect of infarcts on dementia in the Baltimore longitudinal study of aging , 2008, Annals of neurology.
[87] C. Haass,et al. Amyloid at the cutting edge: activation of alpha-secretase prevents amyloidogenesis in an Alzheimer disease mouse model. , 2004, The Journal of clinical investigation.
[88] Hendrik van den Bussche,et al. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials , 2005, BMJ : British Medical Journal.
[89] L. Lue,et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. , 1999, The American journal of pathology.
[90] T. Wisniewski,et al. Amyloid-β immunisation for Alzheimer's disease , 2008, The Lancet Neurology.
[91] L. Candelise,et al. Galantamine for Alzheimer’s Disease and Mild Cognitive Impairment , 2007, Neuroepidemiology.
[92] D. Selkoe. Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.
[93] D. Iarussi,et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. , 1999, American journal of hypertension.
[94] H. Kavirajan. Memantine: a comprehensive review of safety and efficacy. , 2009, Expert opinion on drug safety.
[95] C. Patterson,et al. Comparison studies of cholinesterase inhibitors for Alzheimer's disease , 2004, The Lancet Neurology.
[96] Nathan Herrmann,et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[97] P. Macfarlane,et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.
[98] S H Ferris,et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. , 1997, Alzheimer disease and associated disorders.
[99] J. C. de la Torre,et al. For Personal Use. Only Reproduce with Permission the Lancet Publishing Group. Personal View Is Ad Neurodegenerative or Vascular? Is Ad Neurodegenerative? Is Alzheimer's Disease a Neurodegenerative or a Vascular Disorder? Data, Dogma, and Dialectics , 2022 .
[100] T. Golde. Disease modifying therapy for AD? 1 , 2006, Journal of neurochemistry.
[101] A. Delacourte,et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease , 1999, Neurology.
[102] J. Coyle,et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. , 1982, Science.
[103] Howard Fillit,et al. Economics of dementia and pharmacoeconomics of dementia therapy. , 2005, The American journal of geriatric pharmacotherapy.
[104] Ian G. McKeith,et al. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales , 2001, The Lancet.
[105] J Driver,et al. Modulation of fusiform cortex activity by cholinesterase inhibition predicts effects on subsequent memory. , 2009, Brain : a journal of neurology.
[106] S. Younkin,et al. Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.
[107] C. Pedone,et al. Antipsychotics for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD) , 2008, Current neuropharmacology.
[108] W. Noble,et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[109] I. Deary,et al. The Effects of Antihypertensive Treatment on Cognitive Function: Results from the HOPE Study , 1996, Journal of the American Geriatrics Society.
[110] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[111] Carol Brayne,et al. Age, neuropathology, and dementia. , 2009, The New England journal of medicine.
[112] G C Roman,et al. Brain infarction and the clinical expression of Alzheimer disease. , 1997, JAMA.
[113] W W Offen,et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. , 1997, Archives of neurology.
[114] K. Lanctôt,et al. Management of mild to moderate Alzheimer’s disease and dementia , 2007, Alzheimer's & Dementia.
[115] Jeffrey L. Cummings,et al. Practice parameter: Diagnosis of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .
[116] Alteration in brain presenilin 1 mRNA expression in early onset familial Alzheimer's disease. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[117] Seth Love,et al. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.
[118] G. Schellenberg,et al. Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.
[119] K. Davis,et al. A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.
[120] D. Suh,et al. Drug Persistency of Two Cholinesterase Inhibitors , 2005, Drugs & aging.
[121] S. Arnold,et al. Cool with plaques and tangles. , 2009, The New England journal of medicine.
[122] L. Thal,et al. Choline chloride fails to improve cognition in Alzheimer's disease , 1981, Neurobiology of Aging.
[123] Liang Li,et al. Current experimental therapy for Alzheimer's disease. , 2007, Current neuropharmacology.
[124] J. C. Torre,et al. Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer’s pathogenesis , 2000, Neurobiology of Aging.
[125] D. Leys,et al. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease , 2009, Neurology.
[126] J. Hardy,et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.
[127] Chi Li,et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[128] C. Lyketsos,et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[129] H. Hanyu,et al. SPECT Follow‐Up Study of Cerebral Blood Flow Changes During Donepezil Therapy in Patients with Alzheimer's Disease , 2006, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[130] M. Sano,et al. An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease , 1997, Alzheimer disease and associated disorders.
[131] K. Ashe. A tale about tau. , 2007, The New England journal of medicine.
[132] D. Dickson,et al. The Pathogenesis of Senile Plaques , 1997, Journal of neuropathology and experimental neurology.
[133] H. Fillit,et al. The Economic Benefits of Acetylcholinesterase Inhibitors for Patients with Alzheimer Disease and Associated Dementias , 2004, Alzheimer disease and associated disorders.
[134] H. Braak,et al. Demonstration of Amyloid Deposits and Neurofibrillary Changes in Whole Brain Sections , 1991, Brain pathology.
[135] F. Sherriff,et al. Memantine for dementia. , 2005, The Cochrane database of systematic reviews.
[136] A. Nordberg,et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months , 2002, Neurology.
[137] Xiuzhen Zhang,et al. Valproic acid as a promising agent to combat Alzheimer's disease , 2010, Brain Research Bulletin.
[138] S. Lipton,et al. NMDA receptors: from genes to channels. , 1996, Trends in pharmacological sciences.